Centricity Research

How do I learn more?

If you are interested in learning more about clinical trials, or wish to inquire about out current or future trials, click here to contact us and one of our highly trained staff will be in touch to provide more information.

Migraine Prevention – Biogen – (BHV3000-404)

Migraine is a type of headache that causes intense pain, usually on one side of the head, and can lead to other symptoms such as nausea, vomiting and sensitivity to light and sound. It can last for hours or days and can interfere with daily activities. Treatment can help manage symptoms and reduce the frequency of attacks

Centricity Research is enrolling participants in a Migraine Prevention Study in our Halifax, Nova Scotia location. Compensation may be available for time and travel for qualified participants.

You can learn more about this study by visiting clinicaltrials.gov and entering the protocol number BHV3000-404 or click on see study details

Parkinson’s Disease – Biogen – (283PD201)

Parkinson’s Disease is a neurological disorder that causes movement problems, including tremors and stiffness. It is caused by the loss of dopamine-producing brain cells. This disease also causes mood and cognitive changes, including depression and memory loss. There is no cure for Parkinson’s, but medications and therapy can help manage the symptoms and improve the quality of life of those affected by it.

Centricity Research is enrolling participants in a Parkinson’s Disease Study in our Halifax, Nova Scotia location. Compensation may be available for time and travel for qualified participants.

You can learn more about this study by visiting clinicaltrials.gov and entering the protocol number 283PD201 or click on see study details

Alzheimer’s Disease  – Biogen – (221AD305)

Alzheimer’s Disease is a progressive brain disorder that causes memory loss and difficulty with thinking, problem-solving and communication. It occurs due to the degeneration and death of brain cells leading to a decline in cognitive function. This disease also causes changes in mood and behavior, and patients may experience confusion and disorientation. Currently, there is no cure for Alzheimer’s, but medications and therapy can help manage the symptoms and improve the quality of life of those affected by it.

Centricity Research is enrolling participants in an Alzheimer’s Disease Study in our Halifax, Nova Scotia location. Compensation may be available for time and travel for qualified participants.

You can learn more about this study by visiting clinicaltrials.gov and entering the protocol number 221AD305 or click on see study details

Migraine Botox Injections – Aeon Biopharma, Inc – (ABP-20001)

Migraine is a type of headache that causes intense pain, usually on one side of the head, and can lead to other symptoms such as nausea, vomiting and sensitivity to light and sound. It can last for hours or days and can interfere with daily activities. Treatment can help manage symptoms and reduce the frequency of attacks.

Centricity Research is enrolling participants in a Migraine Botox Injections Study in our Halifax, Nova Scotia location. Compensation may be available for time and travel for qualified participants.

You can learn more about this study by visiting clinicaltrials.gov and entering the protocol number ABP-20001 or click on see study details

Essential Tremor Botox Treatment – AbbVie – (M21-471)

Essential Tremor is a neurological disorder characterized by the involuntary shaking or trembling of certain parts of the body, especially the hands, arms, head or voice. The condition can be triggered by movements or stress and can worsen over time. It is not life-threatening but can cause difficulty with daily activities and have negative effects on the patient’s quality of life. Essential Tremor is treated with medications, lifestyle modifications or surgery depending on the severity of the condition.

Essential Tremor Botox Treatment is a medical procedure where small amounts of Botulinum Toxin Type A (Botox) are injected into the muscles, specifically those that cause involuntary tremors, to reduce it.

Centricity Research is enrolling participants in an Essential Tremor Botox Treatmentstudy in our Halifax, Nova Scotia location. Compensation may be available for time and travel for qualified participants.

You can learn more about this study by visiting clinicaltrials.gov and entering the protocol number M21-471 or click on see study details

Migraine Botox Injections – Aeon Biopharma – (ABP-20002)

Migraine is a type of headache that causes intense pain, usually on one side of the head, and can lead to other symptoms such as nausea, vomiting and sensitivity to light and sound. It can last for hours or days and can interfere with daily activities. Treatment can help manage symptoms and reduce the frequency of attacks. 

Migraine Botox Injection is a medical procedure where small amounts of Botox are injected into the head and neck muscles, with the aim of reducing the frequency and severity of migraine headaches. Botox, a neurotoxin, blocks the nerve signals that cause muscle contractions, which can trigger migraines.

Centricity Research is enrolling participants in a Migraine Botox Injections study in our Halifax, Nova Scotia location. Compensation may be available for time and travel for qualified participants.

You can learn more about this study by visiting clinicaltrials.gov and entering the protocol number ABP-20002 or click on see study details

Early Alzheimer’s Disease – AbbVie – (M22-721)

Early Alzheimer’s Disease refers to the initial stages of the disease when symptoms are mild and may not be easily noticeable. During this stage, cognitive function and memory problems are present but are often attributed to normal aging processes. People with early Alzheimer’s may still function independently but may have difficulty with planning, organization and may become more forgetful. Although the symptoms are mild in the early stages, it is essential to receive an early diagnosis to start the treatment process and plan for future care.

Centricity Research is enrolling participants in an Early Alzheimer’s Disease study in our New Minas, Nova Scotia location. Compensation may be available for time and travel for qualified participants.

You can learn more about this study by visiting clinicaltrials.gov and entering the protocol number M22-721 or click on see study details

Alzheimer’s Disease – AB Science – (AB21004)

Alzheimer’s Disease is a type of health condition that causes memory loss and difficulties with thinking and problem-solving. It happens when the brain cells start to break down and die, leading to a decline in mental function. This disease can also cause changes in mood and behavior, and patients may experience confusion and disorientation. Alzheimer’s Disease starts slowly and gets worse over time. Currently, there is no cure for Alzheimer’s, but medications and therapy can help manage the symptoms and improve the quality of life of those affected by it.

Centricity Research is enrolling participants in an Alzheimer’s Disease study in our New Minas, Nova Scotia location. Compensation may be available for time and travel for qualified participants.

You can learn more about this study by visiting clinicaltrials.gov and entering the protocol number AB21004 or click on see study details

Cardiovascular Disease – Novartis Pharmaceuticals – (CKJX839D12302)

Cardiovascular Disease is a type of health condition that affects the heart and blood vessels. It is a broad term used to describe various diseases such as coronary artery disease, heart failure, heart valve disease, and arrhythmia, among others. Cardiovascular disease is caused by factors like high blood pressure, high cholesterol, smoking, poor diet, and a lack of exercise, which can damage the blood vessels leading to the heart and the heart itself. This damage can lead to serious health issues, including heart attacks, strokes, and heart failure. The prevention and management of cardiovascular disease involve lifestyle changes, medication, and medical procedures, depending on the severity of the case.

Centricity Research is enrolling participants in a Cardiovascular Disease study in our New Minas, Nova Scotia location. Compensation may be available for time and travel for qualified participants.

You can learn more about this study by visiting clinicaltrials.gov and entering the protocol number CKJX839D12302 or click on see study details

Alzheimer’s Disease – Eisai Inc – (BAN2401-G000-303)

Alzheimer’s Disease is a progressive brain disorder that causes memory loss, impaired thinking, and behavioural changes. It is the most common cause of dementia and affects millions of people worldwide. The disease progressively damages the nerve cells in the brain, causing them to degenerate and die, leading to a decline in a person’s cognitive function, memory, and language abilities. There is no known cure for Alzheimer’s disease, but medications and lifestyle interventions can help manage the symptoms and improve the quality of life for patients and their caregivers.

Centricity Research is enrolling participants in an Alzheimer’s Disease study in our New Minas, Nova Scotia location. Compensation may be available for time and travel for qualified participants.

You can learn more about this study by visiting clinicaltrials.gov and entering the protocol number BAN2401-G000-303 or click on see study details

Alzheimer’s Disease – Neurim Pharmaceuticals Ltd – (NEUP11-7)

Alzheimer’s Disease is a type of health condition that causes memory loss and difficulties with thinking and problem-solving. It happens when the brain cells start to break down and die, leading to a decline in mental function. This disease can also cause changes in mood and behavior, and patients may experience confusion and disorientation. Alzheimer’s Disease starts slowly and gets worse over time. Currently, there is no cure for Alzheimer’s, but medication and therapy can help manage the symptoms and improve the quality of life of those affected by it.

Centricity Research is enrolling participants in an Alzheimer’s Disease study in our Halifax, Nova Scotia location. Compensation may be available for time and travel for qualified participants.

You can learn more about this study by visiting clinicaltrials.gov and entering the protocol number NEUP11-7 or click on see study details

Migraine – Biohaven – (BHV3000-404)

Migraine is a type of headache that can cause intense pain, usually on one side of the head. It can also cause other symptoms like nausea, vomiting, and sensitivity to light and sound. Migraines can last for several hours or even days, and the pain can be so severe that it interferes with daily activities. Some people may experience warning signs, called “aura,” before a migraine, such as flashing lights, blind spots, or tingling sensations in the arms or legs. Migraines can be triggered by many factors, including stress, certain foods, hormonal changes, or changes in the sleep pattern. There is no cure for migraines, but they can be treated with medications, lifestyle changes, and other therapies to manage the pain and reduce the frequency of the attacks.

Centricity Research is enrolling participants in a Migraine study in our Halifax, Nova Scotia location. Compensation may be available for time and travel for qualified participants.

You can learn more about this study by visiting clinicaltrials.gov and entering the protocol number BHV3000-404 or click on see study details

Migraine –  AEON Biopharma, Inc. – (ABP-20002)

Migraine is a type of headache that can cause intense pain, usually on one side of the head. It can also cause other symptoms like nausea, vomiting, and sensitivity to light and sound. Migraines can last for several hours or even days, and the pain can be so severe that it interferes with daily activities. Some people may experience warning signs, called “aura,” before a migraine, such as flashing lights, blind spots, or tingling sensations in the arms or legs. Migraines can be triggered by many factors, including stress, certain foods, hormonal changes, or changes in the sleep pattern. There is no cure for migraines, but they can be treated with medications, lifestyle changes, and other therapies to manage the pain and reduce the frequency of the attacks.

Centricity Research is enrolling participants in a Migraine study in our Halifax, Nova Scotia location. Compensation may be available for time and travel for qualified participants.

You can learn more about this study by visiting clinicaltrials.gov and entering the protocol number ABP-20002 or click on see study details

Parkinson’s Disease – Biogen – (283PD201)

Parkinson’s Disease is a health condition that affects the way a person moves. It happens when the brain cells that control movement start to break down and die. Parkinson’s disease can cause shaking or tremors, stiffness in the muscles, and difficulty with coordination and balance. This disease also affects other parts of the brain that control thinking, mood, and behavior. Although there is no cure for Parkinson’s disease, there are treatments available to manage its symptoms and improve the quality of life of those affected by it.

Centricity Research is enrolling participants in a Parkinson’s disease study in our Halifax, Nova Scotia location. Compensation may be available for time and travel for qualified participants.

You can learn more about this study by visiting clinicaltrials.gov and entering the protocol number 283PD201 or click on see study details

Huntington’s Disease – Sage Therapeutics, Inc. – (718-CIH-201)

Huntington’s disease is a genetic disorder that affects the brain cells, specifically the basal ganglia, which is responsible for controlling movement and cognitive functions. 

The symptoms of Huntington’s disease include uncontrolled movements, such as jerking or twitching, and difficulties in controlling voluntary movements, speech, and swallowing. Patients also experience cognitive decline, including memory loss and difficulty in concentrating, and may display changes in personality and behavior.

Currently, there is no cure for Huntington’s disease, and the available treatments can only manage the symptoms of the disease. 

Centricity Research is enrolling participants in a Huntington’s disease study in our Halifax, Nova Scotia location. Compensation may be available for time and travel for qualified participants.

You can learn more about this study by visiting clinicaltrials.gov and entering the protocol number 718-CIH-201 or click on see study details

Alzheimer’s Disease – AB Science – (AB21004)

Alzheimer’s disease is a neurological disorder characterized by progressive memory loss and cognitive decline. It is the most common cause of dementia and affects millions of people worldwide. In Alzheimer’s disease, the brain cells degenerate and die, leading to a steady decline in memory, thinking, and reasoning skills. Other symptoms may include confusion, disorientation, difficulty in communicating, and behavioural changes. Currently, there is no cure for Alzheimer’s disease, but there are treatments available that can help manage the symptoms and improve the quality of life.

Centricity Research is currently enrolling participants in an Alzheimer’s disease study in our Halifax, Nova Scotia location. Compensation may be available for time and travel for qualified participants.

You can learn more about this study by visiting clinicaltrials.gov and entering the protocol number AB21004.

Alzheimer’s Disease – Neurim – (NEUP11-7)

Centricity Research is currently participating in an Alzheimer’s Disease study at our New Minas location.

Alzheimer’s disease is a brain disorder that gets worse over time. It’s characterized by changes in the brain that lead to deposits of certain proteins. Alzheimer’s disease causes the brain to shrink and brain cells to eventually die. Alzheimer’s disease is the most common cause of dementia — a gradual decline in memory, thinking, behavior and social skills. These changes affect a person’s ability to function.

Huntington’s Disease – Roche – (BN42489)

Centricity Research is currently participating in an Alzheimer’s Disease study at our Halifax location.

Huntington’s disease is a rare, inherited disease that causes the progressive breakdown (degeneration) of nerve cells in the brain.

Huntington’s disease symptoms can develop at any time, but they often first appear when people are in their 30s or 40s. If the condition develops before age 20, it’s called juvenile Huntington’s disease. When Huntington’s develops early, symptoms are somewhat different, and the disease may progress faster.

Alzheimer’s Disease Dementia – Biogen –  (221-AD-305)

Centricity Research is currently involved in a phase 2 clinical trial with Biogen, to study the efficacy and safety of BIIB080 for treating people with mild cognitive impairment due to Alzheimer’s Disease (AD) or Mild AD Dementia.

The purpose of this study is to assess the safety (symptoms and medical problems you may experience – known as side effects) and efficacy (whether the study drug improves symptoms) of the study drug in patients who are between the ages of 50 to 80 and have been diagnosed with mild cognitive impairment.

The study will run for approximately 105 weeks, or a little over 2 years. Participants who qualify for this study and agree to participate will receive BIIB080 once on day 1 and then once every 12 weeks for up to 72 weeks or the placebo (a saltwater solution without an active drug). Participation in the study is voluntary, and participants can withdraw at any time. 

Early Alzheimer’s disease (AD) – AbbVie –  (M22-721)

Centricity Research is currently involved in a phase 2 clinical trial with AbbVie, to study the efficacy and safety of ABBV-916 for treating people with early Alzheimer’s Disease.

The purpose of this study is to assess the safety (symptoms and medical problems you may experience – known as side effects) and efficacy (whether the study drug improves symptoms) of the study drug in patients who are between the ages of 50 to 90 and have been diagnosed with stage 3 or Stage 4 AD. 

The study will run for approximately 168 days. Participants who qualify for this study and agree to participate will receive once every 4 weeks intravenous (IV) doses of ABBV-916 or the placebo (a saltwater solution without an active drug). Participation in the study is voluntary, and participants can withdraw at any time. 

Alcohol Use Disorder (AUD) – Clairvoyant Therapeutics –  (CLA-PSY-201)

Centricity Research is currently involved in a phase 2 clinical trial with Clairvoyant Therapeutics, to study the efficacy and safety of psilocybin and psychotherapy for treating people with Alcohol Use Disorder (AUD).

The purpose of this study is to assess the safety (symptoms and medical problems you may experience – known as side effects) and efficacy (whether the study drug improves symptoms) of the study drug in patients who are between the ages of 18 to 70 and have been diagnosed with moderate to severe AUD.

The study will run for approximately 40 weeks. Participants who qualify for this study and agree to participate will receive 2 oral doses of 25mg psilocybin capsules or the placebo (a saltwater solution without an active drug). Participation in the study is voluntary, and participants can withdraw at any time. 

Post-Traumatic Stress Disorder Study- Apex-002-A01

Centricity Research is currently involved in a phase IIb clinical trial with Apex Labs, LTD, to study the efficacy and safety of psilocybin oral solution in treating depression among adults with post-traumatic stress disorder.

The purpose of this study is to assess the safety (symptoms and medical problems you may experience – known as side effects) and efficacy (whether the study drug improves symptoms) of the study drug in patients who are between the ages of 18 and 65 and have been diagnosed with depression and post-traumatic stress disorder.

The study will run for approximately 84 days. Participants who qualify for this study and agree to participate will receive a single dose for 5 consecutive days followed by 2 days off over a 12-week period, for a total of 60 micro-doses. Participation in the study is voluntary, and participants can withdraw at any time. 

Merck Alzheimer’s Disease Study –  MK-1942

Alzheimer’s disease is a type of dementia that impacts approximately 35 million people. Alzheimer’s is a progressive disease that affects an individual’s memory and other brain functions. Common symptoms include confusion and memory loss that disrupt one’s daily life and ability to complete familiar tasks. Other signs of the disease involve difficulty solving problems, poor judgment and decision-making, and changes in personality.

While the risk of developing Alzheimer’s tends to increase with age, the causes of the disease are not fully understood. Current therapies exist; however, research is essential in better understanding the disease and developing improved therapies and treatment options. In this study, we are evaluating the safety and efficacy of an experimental medication as adjunctive therapy in participants with mild to moderate Alzheimer’s disease.

Qualifications:
Ages 55-90
Diagnosed with Alzheimer’s disease
No previous history of stroke or other central nervous system diagnosis

Study Duration: 41 months
Location: Centricity Research, 36 Solutions Drive, Suite 420, Halifax, NS B3S 1B2

Upper Limb Essenial Tremor – AbbVie Inc. – M21-471

Centricity Research is currently involved in a phase 2 clinical trial with Alector Inc., to study the efficacy and safety of AL002 for the treatment of early Alzheimer’s Disease (AD).

The purpose of this study is to assess the safety (symptoms and medical problems you may experience – known as side effects) and efficacy (whether the study drug improves symptoms and how it changes disease progression based on a well known cognitive test scores) of the study drug in patients who are between the ages of 50 to 85 and have AD.

The study will run for approximately 96 weeks. Participants who qualify for this study and agree to participate will receive intravenous injections every 4 weeks, of either the treatment or the placebo (a salt water solution without active drug). Participation in the study is voluntary, and participants can withdraw at any time.

Alzheimer’s Disease – Cassava – PTI-125-06

Centricity Research (formerly True North Clinical Research) is currently involved in phase 3 clinical trial with Cassava Sciences, Inc. to investigate the safety and efficacy of Simufilam in patients with mild-to-moderate Alzheimer’s Disease (AD).

The purpose of this study is to assess the safety (symptoms and medical problems you may experience – known as side effects) and efficacy (whether the study drug slows cognitive and functional decline based on cognitive test scores) of the study drug in patients who are between the ages of 50 to 87 with mild-to-moderate AD.

The study will run for approximately 76 weeks, which is about 1.45 years. Participants who consent and qualify for this study will receive either a twice-daily dose of the study drug in tablet form or placebo (which looks like the study drug, but has no active ingredient in it). Participants will have 9 clinic visits and 1 follow-up phone call at the end of treatment. The study involves various tests and MRI scans. Blood samples will be taken at each clinic visit. Participants must have a study partner, who is willing to take part in the study. Participation in the study is voluntary, and participants can withdraw at any time.

Early Alzheimer’s disease – EVOKE/EVOKE plus

Centricity Research is currently involved in the EVOKE and EVOKE plus studies, phase 3 clinical trials with Novo Nordisk A/S, to study the efficacy and safety of semaglutide, for the investigational treatment of Early Alzheimer’s disease (AD).

The purpose of this study is to assess the safety (symptoms and medical problems you may experience-known as side effects) and efficacy (whether the study drug improves symptoms and how it changes disease progression based on well-known cognitive test scores) of the study drug in patients who are between the ages of 55 to 85.

The study will run for approximately 173 weeks (3 years, 4 months). Participants who qualify for this study will agree to receive a once-daily dose of the study drug in pill form, of either the treatment or placebo (a pill without the active drug). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10 of the clinic visits, participants will have blood samples taken. Participants must have a study partner, who is willing to take part in the study. Participation in the study is voluntary, and participants can withdraw at any time.